| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PRG1 |
| Uniprot No | P10124 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-158 aa |
| 活性数据 | YPT RRARYQWVRC NPDSNSANCL EEKGPMFELL PGESNKIPRL RTDLFPKTRI QDLNRIFPLS EDYSGSGFGS GSGSGSGSGS GFLTEMEQDY QLVDESDAFH DNLRSLDRNL PSDSQDLGQH GLEEDFML |
| 分子量 | 17.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人PRG1蛋白的3篇参考文献概览(注：PRG1相关文献有限，以下为模拟示例)：
---
1. **文献名称**: *"Recombinant human PRG1 regulates synaptic plasticity via lysophosphatidic acid signaling"*
**作者**: Trimbuch, T., et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化了重组人PRG1蛋白，证实其具有水解细胞外信号分子溶血磷脂酸(LPA)的酶活性。实验表明，PRG1通过调节LPA水平影响海马神经元突触可塑性，可能为神经退行性疾病治疗提供新靶点。
---
2. **文献名称**: *"Production and functional characterization of recombinant PRG1 in modulating macrophage polarization"*
**作者**: Lee, S., & Kim, J. H.
**摘要**: 通过哺乳动物细胞系统表达重组人PRG1蛋白，发现其能显著抑制LPS诱导的巨噬细胞M1型极化，并促进抗炎因子IL-10分泌。该蛋白在炎症调控中的潜在作用被首次揭示。
---
3. **文献名称**: *"Structural insights into PRG1-LPA interaction via recombinant protein crystallization"*
**作者**: Zhang, Q., et al.
**摘要**: 利用昆虫细胞表达体系获得高纯度重组人PRG1蛋白，通过X射线晶体学解析其与LPA结合的三维结构。研究发现PRG1的催化口袋具有独特疏水结构域，为开发靶向抑制剂奠定基础。
---
**注意事项**：
PRG1 (Plasticity-Related Gene 1) 相关研究仍处于初期，实际文献可能较少。建议通过数据库(如PubMed、Google Scholar)结合多种关键词(如“PRG1 recombinant”“LPA hydrolase”)进一步检索最新进展。部分内容基于假设性研究场景构建，需结合实际文献修正。
Recombinant human PRG1 (Proteoglycan 1) protein is a cell surface-associated proteoglycan predominantly expressed in the central nervous system (CNS), particularly in neurons. It regulates neural plasticity and axonal guidance by interacting with extracellular matrix components and modulating signaling pathways. Structurally, PRG1 consists of a core protein linked to glycosaminoglycan (GAG) chains, enabling roles in cell adhesion, migration, and signal transduction. A key function is its ability to bind and neutralize lysophosphatidic acid (LPA), a lipid mediator involved in neuroinflammation and neurodegeneration. By sequestering LPA, PRG1 maintains synaptic stability and prevents excessive neurite outgrowth, crucial for limiting maladaptive neural rewiring post-injury. PRG1-deficient models exhibit impaired axonal regeneration and heightened neuroinflammation, underscoring its role in CNS repair. Dysregulation of PRG1 is linked to neurological disorders like epilepsy, multiple sclerosis, and spinal cord injury, where altered expression correlates with disease progression. Recombinant PRG1 is used to explore therapies targeting LPA signaling, neuroprotection, and neural regeneration, offering potential for treating CNS injuries and degenerative diseases. Its dual role in maintaining neural homeostasis and modulating injury responses highlights its relevance in neuroscience and translational research.
×
